Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction

Pharmacotherapy

Volumn 16, Issue 2 I, 1996, Pages 301-305

  Sketris, Ingrida S ^a,b   Wright, Matthew R ^a   West, Michael L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CASE REPORT; DRUG CLEARANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE;

ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CYCLOSPORINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PNEUMONIA;

EID: 0030005034     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;44:117-64
2. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-430. Comparison with other macrolides J Pharmacol Exp Ther 1989;250:746-51
3. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR. Cyclosporine-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987,23.776-8
4. Gupta SK, Bakran A, Johnson RWG, Rowland M Cyclosporine-eryihromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989;27.475-81.
5. Vereerstraeten P, Thiry P, Kinnaert P, Toussaint C. Influence of erythromycin on cyclosporine kinetics. Transplantation 1987, 44 155-6
6. Wadhwa NK, Schroeder TJ, O'Flaherty E, et al. Interaction between cyclosporine and erythromycin in a kidney and pancreas allograft recipient. Ther Drug Monit 1987;9:123-5.
7. Godin JRP, Sketris IS, Belitsky P. Erythromycin-cyclosporine interaction [letter]. Drug Intell Clin Pharm 1986;20:504-5
8. Gersema LM. Suspected drug interaction between cyclosporine and clarithromycin J Heart Lung Transplant 1994;13.343-5
9. Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 1994,58:725-7
10. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporine. Part I. Clin Pharmacokinet 1990;19 319-32.
11. Bauer S, Brockmoller J, Kewitz H, Roots I The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A Int J Clin Pharmacol Ther Toxicol 1992;30:540-2.
12. Omar G, Shah IA, Thomson AW, Whiting PH, Burke MD. FK506 inhibition of cyclosporin metabolism by human liver microsomes. Transplant Proc 1991;1:934-5.
13. Hebert MF, Roberts JP, Prueksaritanot T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
14. Gomez D, Hebert MF, Benet LZ. The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine Clin Pharmacol Ther 1993;55:209.
15. Anonymous. Biaxin product monograph In: Krogh CME, ed. Compendium of pharmaceuticals and specialities, 30th ed. Ottawa: Canadian Pharmaceutical Association, 1995.
16. Periti P, Mazzei T, Mini E, Noveli A. Pharmacokinetic drug interactions of niacrolides. Clin Pharmacokinet 1992;23. 106-31
17. Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporine-associated gingival hyperplasia with azithromycin therapy [letter]. N Engl J Med 1995;332:753-4.